Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2008

Charlesson Awarded Almost $1.6M from NIH to Advance AMD Mouse Model and Ocular Disease Drug Candidate

  • Charlesson received two SBIR grants from the NIH totaling close to $1.6 million to support development of a nanoparticle-formulated therapy for eye disease and a preclinical genetic animal model for age-related macular degeneration (AMD).

    Specifically, the firm obtained $210,357 to validate and commercialize its mouse model of AMD. Charlesson also received  over $1.38 million in a phase 2 SBIR grant to develop CLT-004 for treating AMD, diabetic retinopathy, and diabetic macular edema. These funds will be used to develop IND-enabling efficacy, safety, and toxicity profiles.

    CLT-004 is a small molecule that reduces retinal inflammation and vascular leakage, according to Charlesson. The firm is developing a sustained-release nanoparticle formulation of CLT-004 to treat blinding retinal disease.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »